Development of Prolonged Release Microspheres of Metformin Hydrochloride Using Ion Exchange Resins

Aim To prepare the prolonged-released microspheres of mefformin hydrochloride. Methods Ion-exchange resin-drug mefformin hydrochloride complexes were prepared as core materials, and followed by coating using ethylcellulose （EC） by the emulsion solvent diffusion technique. The release rate of mefformin from the microcapsules was highly dependent on the encapsulating formulation, thus being used as an index for formulation screening. Orthogonal experiments were performed to optimize the coating formulation. Results The final chosen formulation for coating of mefformin microcapsules were as follows： （ 1 ） the ratio of EC （20cps） to EC （45cps） was 50：50; （2） the ratio of plasticizer to coating materials was 20% ;and （3） the ratio of resin-mefformin complexes to coating materials was 5 ： 1. Conclusion The prolonged release microspheres of mefformin hydrochloride were successfully prepared.

Preparation and <i>in Vitro</i>Drug Release Evaluation of Once-Daily Metformin Hydrochloride Sustained-Release Tablets

The objective of this study was to develop once-daily metformin hydrochloride sustained-release tablets (MHSRT) and evaluate their in vitro release behavior. MHSRT were prepared by the film coating method. The in vitro drug release rate of MHSRT and the commercial tablets Fortamet? made in the United States of America in water was fitted with zero order kinetic equation, and Ritger-Peppas kinetic equation in 0.1 M HCl and pH 6.8-phosphate buffer, respectively. The similarity factor f2 values of MHSRT in three different dissolution medium were 82, 80 and 74, respectively in comparison with imported Fortamet?, which were all greater than 50. The results of storage-stability showed that MHSRT were stable for at least 6 months under stress condition (40℃ ± 2℃, RH 75% ± 5%). Therefore, in this study, MHSRT were successfully prepared using optimized formulation technologies that meet mass produce. The in vitro release behavior of MHSRT was almost similar to that of imported Fortamet?.

Effect of Temperature on Volumetric and Viscometric Properties of Homologous Amino Acids in Aqueous Solutions of Metformin Hydrochloride

Density（ρ）and viscosity（η）are measured for glycine,DL-α-alanine DL-α-valine,and DL-α-leucine in 0.05,0.10,0.15 and 0.20 mol·L^-1aqueous metformin hydrochloride at 308.15,313.15 and 318.15 K.The measured values are used to estimate some important parameters,such as partial molal volume Vφ,standard partial molal volume Vφ^0,transfer volume ΔVφ^0,hydration number nH,the second derivative of infinite dilution of partial molal volume with respect to temperature,viz., ^2 Vφ^0 /T^2,viscosity B-coefficient,variation of B with temperature,viz., dB/dT,free energy of activation per mole of solvent Δμ1^＊0 and solute Δμ2^0＊ of the amino acids.These parameters are interpreted in terms of solute-solute and solute-solvent interactions and structure making/breaking ability of solutes in the given solution.In addition,Vφ^0,0 ΔVφ^0,viscosity B-coefficient,ΔB and Δμ2 ^0＊ are split into group contributions（NH3^＋ COO ^-）and -CH2 of the amino acids using their linear correlation and their behavior is discussed.

<i>In-Vitro</i>Antiproliferative Analysis of Metformin Hydrochloride on Androgen-Sensitive, LNCAP and Androgen-Insensitive, PC-3 Human Prostate Cancer Cell Lines

Prostate cancer is one of the diseases worldwide that causes cancer-related deaths in men. Metformin is an antidiabetic drug that has been in use for over two decades for the treatment of Type II Diabetes mellitus (DM2). The purpose of this study was to evaluate the anti-proliferative property of metformin hydrochloride on androgen-sensitive, LNCAP and androgen-insensitive, PC-3 human prostate cancer cell lines at different concentrations (μM and mM) using 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay. Metformin hydrochloride displayed a stronger cytotoxicity on the androgen-insensitive PC-3 than on the androgen-sensitive human prostate cancer cell lines. For both cell lines, the antiproliferative activity of metformin hydrochloride was best displayed at 0.1 mM concentration with average cell death percentage of 60% after 120-hour exposure.

Conductometric Titration of Metformin Hydrochloride: Simulation and Experimentation

In order to teach students,the importance of conductometric titrations in this work,we present a laboratory experiment to quantify the amount of metformin hydrochloride in a tablet.The quantification was carried out through the evaluation of the chloride by silver nitrate.The titration and the end point were followed by conductometric titration,as well as by potentiometric and visually by the Volhard method.In addition,the theoretical conductivities of the metformin hydrochloride solution were calculated when known volumes of titrant are added,using the limit conductivity data for each of the ions present in the literature.To simulate the conductometric titration,the calculated conductivity values were plotted based on the volume of silver nitrate added.A comparison between techniques is made in order to determine the best monitoring method,being this one conductimetry to detect the equivalence point for metformin hydrochloride with 0.99±0.03,according to relative standard deviation(%RSD).Simulated titration curves adequately describe obtained results in an experimental way.The conductometric titration is the best method for quantification since it shows less dispersion between obtained results and has the highest concordance among results.Their application is shown through the analysis and conductometric titration simulations.

Development and Validation of a Method for Simultaneous Determination of Metformin Hydrochloride and Sitagliptin Phosphate in a Formulation by RP-HPLC

Present study was aimed to develop and validate a reverse-phase high-performance liquid chromatography method for simultaneous determination of sitagliptin phosphate and metformin hy-drochloride in a marketed formulation. The drug separation was performed on Hibar-240, Li-chrosphere-100 C18 ODS (250 × 4.6 mm, 5 μm) column, at a flow rate of 1 mL/min. The mobile phase used was a mixture of methanol: potassium di-hydrogen phosphate buffer at a ratio of 70:30 v/v. The detection was carried out at a wavelength of 266 nm. The retention times of sitagliptin phosphate and metformin hydrochloride were found as 6.1 and 4.9 min respectively. Linear calibration curves with good correlation coefficients were obtained over the concentration ranges of 10 - 50 μg/mL for sitagliptin and 20 - 100 μg/mL for metformin. The limit of detection was 0.016 and 0.14 μg/mL and the limit of quantification was 0.048 and 0.42 μg/mL for sitagliptin phosphate and metformin hydrochloride respectively. Validation of the method demonstrated system selectivity, specificity, linearity, accuracy and precision. The developed method was found useful in the simultaneous analysis of sitagliptin phosphate and metformin hydrochloride in formulation.

Effect of vildagliptin as add-on therapy to a low-dose metformin

AIM:To evaluate the efficacy and safety of the addition of vildagliptin to low-dose metformin and compare it to an uptitration of metformin in type 2 diabetes mellitus(T2DM) patients who have inadequate control with metformin monotherapy.METHODS:Eligible patients were randomized to receive vildagliptin 100 mg qd or metformin(500 mg qd for 2 wk and then 500 mg bid) added to open label me tformin 500 mg bid for the 24 wk.The primary endpoi nt was baseline to endpoint hemoglobin A1c(HbA1c) change.RESULTS:The adjusted mean change from baseline in HbA1c at the 24th wk was-0.51% in the vildagliptin/metformin group(mean baseline HbA1c:7.4%) and-0.37% in the metformin monothera py group(mean baseline HbA1c:7.3%).The mean diffe rence was-0.14% with 95% Confidence Interval(-0.24%,-0.05%).As non-inf e riority(margin of 0.4%) was achieved,a test for superiority was performed.This test showed statistically significant superiority of the combination over monotherapy group(P = 0.002).Gastrointestinal(GI) adverse events were signif icantly more frequent in the metformin group than the combin ation group(21.0% vs 15.4%,P = 0.032).CONCLUSION:In patients with T2DM inadequately controlled with metformin up to 1000 mg daily,the addition of vildagliptin 100 mg daily achieved larger HbA1c reduction with fewer GI events than with increa sing the metformin dose.

Mechanism Based Pharmacokinetic Pharmacodynamic Modeling of Vildagliptin as an Add-on to Metformin for Subjects with Type 2 Diabetes

Various drugs are used to maintain normoglycemia in subjects with type 2 diabetes mellitus.The combination of the drugs from different classes in one single tablet may enhance the effectiveness of the anti-diabetic drugs.To investigate the impact of combining drugs on the glucose regulation of subjects with type 2 diabetes,we propose a pharmacokinetic/pharmacodynamics(PK/PD)mathematical modeling approach for a combination of metformin and vildagliptin drugs.In the proposed modeling approach,two separate PK models representing oral administration of metformin and vildagliptin for diabetic subjects are interconnected to a PD model comprising a detailed compartmental physiological model representing the regulatory effect of insulin,incretins and glucagon hormones on glucose concentration in a human body.The impact of doses of individual drugs and their combination on the blood glucose concentration of a group of type 2 diabetic subjects is investigated.It is indicated that while administration of individual drugs reduces the blood glucose levels,since they have separate mechanisms of action,combining them synergizes lowering the blood glucose levels.

基于UHPLC-Orbitrap HRMS的盐酸二甲双胍及其片剂中N-亚硝基二甲胺的测定

建立了测定盐酸二甲双胍及其片剂中N-亚硝基二甲胺(NDMA)的超高效液相色谱-静电场轨道阱高分辨质谱法(UHPLC-Orbitrap HRMS)。采用Waters XSelect CSH C18色谱柱(150 mm×3.0 mm,2.5μm),以0.1%甲酸水溶液-0.1%甲酸甲醇溶液为流动相,梯度洗脱;大气压化学电离源(APCI),正离子模式,产物离子扫描。结果显示NDMA在1~100 ng/mL范围内线性关系良好,检测限和定量限分别为0.3 ng/mL和0.9 ng/mL,原料药和片剂的平均加标回收率分别为101.4%和98.5%。本方法专属性好、灵敏度和准确度高,适用于盐酸二甲双胍及其片剂中痕量遗传毒性杂质NDMA的检查与控制。

德谷胰岛素联合西格列汀二甲双胍治疗难治性2型糖尿病的临床研究

目的探讨德谷胰岛素联合西格列汀二甲双胍治疗难治性2型糖尿病患者的临床效果。方法选取2021年5月至2023年3月我院收治的84例难治性2型糖尿病住院患者,随机分为试验组(42例)和参照组(42例)。参照组采用西格列汀二甲双胍治疗,试验组采用德谷胰岛素联合西格列汀二甲双胍治疗。比较两组的血糖水平、低血糖发生情况。结果治疗12周后,两组空腹血糖(FPG)、餐后2h血糖(2hPBG)和糖化血红蛋白(HbA1c)水平降低,且试验组FPG、2hPBG、HbA1c水平低于参照组(P<0.05)。试验组治疗期间低血糖发生率为11.90%,与参照组的9.52%无统计学差异(P>0.05)。结论德谷胰岛素联合西格列汀二甲双胍治疗难治性2型糖尿病患者的控糖效果更佳,且未明显增加低血糖发生风险,安全性较高,值得临床推广。

妊娠期糖尿病患者应用盐酸二甲双胍联合门冬胰岛素的效果研究

目的:探究妊娠期糖尿病(GDM)患者应用盐酸二甲双胍联合门冬胰岛素的效果。方法:从2021年9月至2023年8月间郑州大学第一附属医院产科收治的GDM患者中择取80例展开研究,按随机数字表法划分为对照组与观察组,各40例。对照组单独应用门冬胰岛素治疗,观察组则予以盐酸二甲双胍联合门冬胰岛素的给药方式治疗,比较两组患者的临床治疗效果、血糖指标水平、胰岛素指标水平和不良妊娠结局。结果:治疗前,两组患者的各项血糖、胰岛素指标水平比较,差异均无统计学意义(P>0.05);治疗1个月后,观察组患者的空腹血糖(FPG)、餐后2 h血糖(2h PG)、糖化血红蛋白(HbA1c)、胰岛素抵抗指数(Homa-IR)水平低于对照组,空腹胰岛素(FINS)、胰岛β细胞功能指数(Homa-β)水平则高于对照组,差异均具有统计学意义(P<0.05)。比较两组的不良妊娠结局发生率,观察组低于对照组,差异均具有统计学意义(P<0.05)。结论:对于经过饮食+运动控制后,血糖的水平仍然没有达到良好控制效果的GDM患者,给予盐酸二甲双胍联合门冬胰岛素治疗,不但能将患者的血糖控制在更低的水平,改善胰岛的功能,而且还能减少不良妊娠结局的发生。

二甲双胍恩格列净片治疗2型糖尿病合并HFpEF的临床效果

目的:探讨二甲双胍恩格列净片治疗2型糖尿病(T2DM)合并射血分数保留性心力衰竭(HFpEF)患者的临床效果和安全性。方法:选取2021年10月—2022年9月保定市第一中心医院80例T2DM合并HFpEF患者,通过随机数字表法将其分为观察组(n=40)和对照组(n=40)。对照组给予常规药物治疗,观察组在对照组的用药基础上联合二甲双胍恩格列净片治疗。两组均接受为期6个月的连续治疗。对比两组血糖指标、心功能指标及不良反应发生情况。结果:治疗后,两组空腹血糖(FBG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(HbA1c)均较治疗前下降,且观察组均低于对照组(P<0.05)。治疗后,两组左室射血分数(LVEF)、左室舒张末径(LVEDD)、左室收缩末径(LVESD)、脑钠肽(BNP)均优于治疗前,且观察组均优于对照组(P<0.05)。观察组不良反应发生率(5.0%)低于对照组(22.5%),差异有统计学意义(P<0.05)。结论:二甲双胍恩格列净片治疗2型糖尿病合并HFpEF临床效果显著,能够使患者的血糖水平下降并提高心功能相关指标,同时安全性较高。

盐酸二甲双胍与瑞格列奈联用治疗糖尿病的临床优势评价

目的分析盐酸二甲双胍与瑞格列奈联用治疗糖尿病的临床优势。方法选取2020年7月—2023年7月泉州市泉港区医院中医科收治的220例糖尿病患者为研究对象,以抽签法进行分组,每组110例。对照组行盐酸二甲双胍治疗,观察组行盐酸二甲双胍与瑞格列奈联用治疗,比较两组临床疗效。结果观察组临床总有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,观察组糖代谢指标低于对照组,血糖达标时间及住院时间短于对照组,差异有统计学意义(P均<0.05)。治疗后,相比于对照组,观察组的血浆胰岛素、胰岛素抵抗指数更低,胰岛素β细胞功能指数更高,差异有统计学意义(P均<0.05)。观察组不良反应发生率为9.09%,与对照组的4.55%相比,差异无统计学意义(P>0.05)。结论盐酸二甲双胍与瑞格列奈联用治疗糖尿病可提高疗效,调整糖代谢指标、胰岛素指标,安全性较高。

Porcine enteric alphacoronavirus infection increases lipid droplet accumulation to facilitate the virus replication

Coronaviruses are widely transmissible between humans and animals, causing diseases of varying severity. Porcine enteric alphacoronavirus(PEAV) is a newly-discovered pathogenic porcine enteric coronavirus in recent years, which causes watery diarrhea in newborn piglets. The host inflammatory responses to PEAV and its metabolic regulation mechanisms remain unclear, and no antiviral studies have been reported. Therefore, we investigated the pathogenic mechanism and antiviral drugs of PEAV. The transcriptomic analysis of PEAV-infected host cells revealed that PEAV could upregulate lipid metabolism pathways. In lipid metabolism, steady-state energy processes, which can be mediated by lipid droplets(LDs), are the main functions of organelles. LDs are also important in viral infection and inflammation. In infected cells, PEAV increased LD accumulation, upregulated NF-κB signaling, promoted the production of the inflammatory cytokines IL-1β and IL-8, and induced cell death. Inhibiting LD accumulation with a DGAT-1 inhibitor significantly inhibited PEAV replication, downregulated the NF-κB signaling pathway, reduced the production of IL-1β and IL-8, and inhibited cell death. The NF-κB signaling pathway inhibitor BAY11-7082 significantly inhibited LD accumulation and PEAV replication. Metformin hydrochloride also exerted anti-PEAV effects and significantly inhibited LD accumulation, downregulated the NF-κB signaling pathway, reduced the production of IL-1β and IL-8, and inhibited cell death. LD accumulation in the lipid metabolism pathway therefore plays an important role in the replication and pathogenesis of PEAV, and metformin hydrochloride inhibits LD accumulation and the inflammatory response to exert anti-PEAV activity and reducing pathological injury. These findings contribute new targets for developing treatments for PEAV infections.

2型糖尿病患者采用达格列净片联合盐酸二甲双胍缓释片治疗的临床效果

目的探索2型糖尿病行达格列净片+盐酸二甲双胍缓释片治疗的优势。方法选取大田县中医院于2021年1月—2023年12月收治的139例2型糖尿病患者为研究对象,按照随机抽签方式将患者分为两组,对照组69例,给予盐酸二甲双胍缓释片治疗,观察组70例,开展达格列净片+盐酸二甲双胍缓释片治疗,比较两组临床治疗效果、血糖指标、血脂指标、体质指数、同型半胱氨酸、胰岛功能和不良反应。结果观察组总有效率(97.14%)高于对照组(88.41%),差异有统计学意义(χ^(2)=3.973,P<0.05)。治疗前两组血糖、血脂指标、体质指数、同型半胱氨酸对比,差异无统计学意义(P均>0.05);治疗后观察组血糖、血脂指标、体质指数、同型半胱氨酸低于对照组,差异有统计学意义(P均<0.05)。治疗前两组胰岛功能对比,差异无统计学意义(P>0.05);治疗后观察组胰岛功能优于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论达格列净片+盐酸二甲双胍缓释片可以有效改善患者血糖指标,保证血糖稳定,同时改善患者胰岛功能,降低对机体产生的副作用,安全性良好。

芪丹颗粒联合盐酸二甲双胍对脾虚痰瘀型2型糖尿病患者胰岛素抵抗的影响

目的:观察芪丹颗粒联合盐酸二甲双胍对脾虚痰瘀型2型糖尿病患者胰岛素抵抗、血清核因子-κB(NF-κB)及肿瘤坏死因子-α(TNF-α)的影响。方法:选取100例脾虚痰瘀型2型糖尿病患者,按随机数字表法分为治疗组及对照组各50例。对照组给予盐酸二甲双胍治疗,治疗组给予二甲双胍联合芪丹颗粒治疗。2组均治疗8周。比较2组临床疗效,比较2组治疗前后中医证候积分、胰岛素抵抗指数(HOMA-IR)、体质量指数(BMI)、腹围(AC)、血脂[总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HLD-C)]、血清NF-κB、TNF-α水平的变化。结果:治疗后,对照组与治疗组临床疗效总有效率分别为80.00%、94.00%,2组比较,差异有统计学意义(P<0.05)。治疗后,2组中医证候积分均较治疗前下降(P<0.05),治疗组中医证候积分低于对照组(P<0.05)。治疗后,2组HOMA-IR、BMI、AC指标值均较治疗前下降(P<0.05),治疗组HOMA-IR、BMI、AC指标值均低于对照组(P<0.05)。治疗后,2组TC、TG、LDL-C水平均较治疗前下降(P<0.05),HLD-C水平均较治疗前上升(P<0.05);治疗组TC、TG、LDL-C水平均低于对照组,差异有统计学意义(P<0.05),HDL-C水平与对照组比较,差异无统计学意义(P>0.05)。治疗后,2组血清NF-κB、TNF-α水平均较治疗前下降,治疗组血清NF-κB、TNF-α治疗前后比较,差异有统计学意义(P<0.05);治疗组血清NF-κB、TNF-α水平均低于对照组(P<0.05)。结论:芪丹颗粒联合盐酸二甲双胍能改善脾虚痰瘀型2型糖尿病患者胰岛素抵抗,下调血清NF-κB、TNF-α水平,改善脂肪组织的炎症反应,缓解临床症状。

吡格列酮二甲双胍片联合达格列净片治疗2型糖尿病的疗效及对糖脂代谢、血清CRP、MMP-9水平的影响

目的:分析吡格列酮二甲双胍片联合达格列净片治疗2型糖尿病(Diabetes mellitus type 2,T2DM)的疗效及对糖脂代谢、血清C反应蛋白(C-reactive Protein,CRP)、基质金属蛋白酶-9(Matrix metalloproteinas-9,MMP-9)水平的影响.方法:以治疗方案的不同将我院2018年1月至2022年1月接收的102例T2DM患者分为参照组(吡格列酮二甲双胍片治疗)和联合组(吡格列酮二甲双胍片+达格列净片治疗),两组各51例.观察治疗3 m后疗效、治疗期间不良反应.于治疗前及治疗后以高效液相法测定糖化血红蛋白(Glycosylated hemoglobin,HbAlc);以放射免疫分析法测定空腹胰岛素(Fasting insulin,FIns);用血糖仪检测餐后2 h血糖(2 h postprandial blood glucose,2hPG)、空腹血糖(Fasting blood-glucose,FPG);同时采用全自动生化分化仪以终点法检测甘油三酯(Triglyceride,TG)、高密度脂蛋白胆固醇(High density lipoprotein cholesterol,HDL-C)、总胆固醇(Total cholesterol,TC)、低密度脂蛋白胆固醇(Low density lipoprotein cholesterol,LDL-C)水平.结果:联合组总有效率高于参照组(P<0.05);与治疗前相比,治疗后两组2hPG、FPG、HbAlc、FIns水平均降低(P<0.05),其中联合组更为显著(P<0.05);与治疗前相比,治疗后两组TG、TC、LDL-C水平均降低,HDL-C升高(P<0.05),其中联合组变化更为显著(P<0.05);与治疗前相比,治疗后两组CRP、MMP-9、CysC、Hcy水平均降低(P<0.05),其中联合组更为显著(P<0.05);联合组不良反应总发生率与参照组相比无明显差异(P>0.05).结论:吡格列酮二甲双胍片联合达格列净片治疗T2DM疗效显著,能改善糖脂代谢,减轻炎症,降低并发症发生率,且较安全可靠.

高效液相色谱-质谱法同时测定药品中10种亚硝胺类基因毒性杂质

建立了超高效液相色谱-质谱联用法同时测定盐酸二甲双胍片、盐酸雷尼替丁胶囊、阿奇霉素原料药和氯沙坦钾原料药中10种N-亚硝胺类基因毒性杂质的含量。采用Kintex F5柱(100 mm×3 mm,2.7μm)为分离柱,以0.1%(体积分数)甲酸水-甲醇作为流动相,流量为0.6 mL/min,梯度洗脱,柱温为40℃,进样量为5μL。离子源为大气压化学电离源,采用多反应监测模式进行正离子扫描。10种N-亚硝胺类基因毒性杂质的质量浓度在1.0~104.2 ng/mL的线性范围内与色谱峰面积线性关系良好,相关系数均大于0.9995,检出限为0.1004~0.1042 ng/mL,定量限为0.0335~0.0347 ng/mL。样品平均加标回收率为91.73%~101.31%,测定结果的相对标准偏差为1.08%~3.67%(n=9)。该方法专属性强、灵敏度高,适用于同时测定盐酸二甲双胍、盐酸雷尼替丁、阿奇霉素和氯沙坦钾中的10种N-亚硝胺类基因毒性杂质。

维格列汀联合二甲双胍治疗肥胖2型糖尿病患者的效果

目的:观察维格列汀联合二甲双胍治疗肥胖2型糖尿病患者的效果。方法:选取2021年1月至2023年1月该院收治的102例肥胖2型糖尿病患者进行前瞻性研究,按随机数字表法将其分为观察组和对照组各51例。对照组采用二甲双胍治疗,观察组在对照组基础上联合维格列汀治疗,比较两组治疗前后糖代谢指标[空腹血糖(FBG)、餐后2 h血糖(2hPG)、糖化血红蛋白(HbA1c)]水平、脂代谢指标[总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)和高密度脂蛋白胆固醇(HDL-C)]水平,脂联素和趋化素水平,临床疗效,以及治疗期间不良反应发生率。结果:治疗后,观察组FBG、2hPG、HbA1c、TC、TG、LDL-C水平均低于对照组,HDL-C水平高于对照组,差异有统计学意义(P<0.05);观察组脂联素水平高于对照组,趋化素水平低于对照组,差异均有统计学意义(P<0.05);观察组治疗总有效率为96.08%(49/51),高于对照组的74.51%(38/51),差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:维格列汀联合二甲双胍治疗肥胖2型糖尿病患者可提高治疗总有效率和脂联素水平,改善脂代谢指标水平,降低糖代谢指标和趋化素水平,效果优于单纯二甲双胍治疗。

利拉鲁肽注射液联合盐酸二甲双胍片治疗肥胖2型糖尿病患者的临床探讨

目的 探究利拉鲁肽注射液结合盐酸二甲双胍在肥胖2型糖尿病患者中的诊疗效果。方法 选取2018年1月—2022年1月宜兴市第二人民医院接诊的96例肥胖2型糖尿病患者为研究对象,将其按照数表法分成两组,每组48例。对照组治疗方案为口服盐酸二甲双胍片,观察组治疗方案为利拉鲁肽注射液+二甲双胍片,两组患者均治疗3个月,对比两组患者治疗效果。结果 治疗前,两组患者血糖水平、胰岛功能以及体质指数、腰臀比对比,差异无统计学意义(P均>0.05);治疗后,观察组空腹血糖、餐后2 h血糖、糖化血红蛋白水平、胰岛素抵抗指数、体质指数和腰臀比均低于对照组,观察组空腹胰岛素、胰岛细胞功能指数高于对照组,差异有统计学意义(P均<0.05)。结论 利拉鲁肽结合二甲双胍可同时改善肥胖2型糖尿病患者的胰岛功能和体重,还能降低其腰臀比,效果显著。